Current status of immunotherapy for non-small cell lung cancer

Nowadays, lung cancer is still the deadliest oncological disease in the world. Among them, non-small cell lung cancer (NSCLC) accounts for 80%∼85% of all lung cancers, and its 5-year survival rate is less than 15%, making the situation critical. In the past decades, despite some clinical advances in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Tao, Xiong, Yilin, Zeng, Yufei, Wang, Yan, Zeng, Jing, Liu, Jie, Xu, Shangfu, Li, Li-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606217/
https://www.ncbi.nlm.nih.gov/pubmed/36313314
http://dx.doi.org/10.3389/fphar.2022.989461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606217/
https://www.ncbi.nlm.nih.gov/pubmed/36313314
http://dx.doi.org/10.3389/fphar.2022.989461

Ejemplares similares